Skin Analytics uses its DERM system to triage skin cancer by analyzing dermatoscopic images captured with a smartphone and a special lens to classify lesions as malignant, pre-malignant, or benign within milliseconds. This enables safe discharge of benign cases, reduces unnecessary biopsies, and fast-tracks high-risk patients to specialists. DERM is an AI as a Medical Device with regulatory clearances (Class III CE in Europe and Class IIa UKCA in the UK) and is integrated into teledermatology pathways, primarily serving the NHS and private insurers like Bupa and Vitality. The goal is to cut dermatology backlogs, improve skin cancer outcomes, and expand access to Europe, Australia, and the US after a Series B funding round in 2025.
Company Size
51-200
Company Stage
Series B
Total Funding
$32.8M
Headquarters
London, United Kingdom
Founded
2012
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?